lenalidomide has been researched along with clarithromycin in 20 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (clarithromycin) | Trials (clarithromycin) | Recent Studies (post-2010) (clarithromycin) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 7,149 | 1,606 | 2,504 |
| Protein | Taxonomy | lenalidomide (IC50) | clarithromycin (IC50) |
|---|---|---|---|
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 5.5 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 3.3113 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.0903 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F | 1 |
| Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F | 1 |
| Agrawal, YP; Cesarman, E; Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furman, RR; Jayabalan, D; Lee, JW; Lent, R; Leonard, JP; Mark, T; Matthew, S; Mazumdar, M; Niesvizky, R; Pearse, RN; Wang, YL | 1 |
| Chen-Kiang, S; Coleman, M; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Jayabalan, DS; Kumar, S; Kyle, RA; Lacy, MQ; Leonard, J; Lust, JA; Mark, T; Niesvizky, R; Pearse, R; Rajkumar, SV; Roy, V; Stewart, AK; Witzig, TE | 1 |
| Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M | 1 |
| Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F | 1 |
| Borrello, I; Ghosh, N; Huff, CA; Tucker, N; Wozney, J; Zahurak, M | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Abe, T; Fujii, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Sakurai, T; Sato, M; Usami, M; Yamada, M; Yoshida, M | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Becker, PS; Bensinger, W; Holmberg, LA | 1 |
| Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M | 1 |
| Abumiya, M; Kanno, S; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Alegre, A; Arguiñano, JM; Arnao, M; Bladé, J; Calasanz, MJ; Casanova, M; Cedena, MT; Coleman, M; Cortés-Rodríguez, M; Couto, MDC; de Arriba, F; de la Rubia, J; Encinas, C; Escalante, F; García-Sánchez, R; Garzón, S; Gironella, M; González, E; González, MS; González-Calle, V; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín, J; Martín, ML; Martín-Sánchez, G; Mateos, MV; Niesvizky, R; Ocio, EM; Oriol, A; Paiva, B; Pérez-Persona, E; Puig, N; Ríos, R; Rosiñol, L; San-Miguel, JF; Teruel, AI; Vale, AM | 1 |
| Allan, JN; Boussi, L; Boyer, A; Coleman, M; Ely, S; Flicker, K; Forsberg, PA; Jayabalan, D; Lakritz, S; Liotta, B; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Ribadeneyra, D; Rossi, AC | 1 |
| Bonomini, L; Devizzi, L; Domènech, ED; Esposito, F; Ferreri, AJM; Guillermo, AL; Kiesewetter, B; Mannina, D; Merli, M; Pirosa, MC; Raderer, M; Salar, A; Sassone, M; Tucci, A; Visco, C; Zucca, E | 1 |
3 review(s) available for lenalidomide and clarithromycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2017 |
7 trial(s) available for lenalidomide and clarithromycin
| Article | Year |
|---|---|
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Time Factors | 2008 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cells; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clarithromycin; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide; Thrombocytopenia | 2010 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2021 |
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Treatment Outcome | 2021 |
IELSG40/CLEO phase II trial of clarithromycin and lenalidomide in relapsed/refractory extranodal marginal zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Treatment Outcome | 2023 |
10 other study(ies) available for lenalidomide and clarithromycin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Clarithromycin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Thalidomide | 2008 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2013 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Immunoglobulin A; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |